|
Events Column |
|
|
10/14
5:00 pm - 7:30 pm
MIT Enterprise Forum of CT. Panel of Entrepreneurs on
Funding Technology Startups. New Haven Lawn Club, New Haven.
more |
|
10/15
6:30 pm - 9:30 pm
LES CT Chapter: "The Birth of Kolltan
Pharmaceuticals." Horchow Hall, 55 Hillhouse Avenue, New
Haven. more
|
|
|
10/21
4:00 pm - 6:00 pm
CURE/Yale BioHaven Entrepreneurship Series: Cara Therapeutics.
Anlyan Center, Yale Medical School, New Haven. more
|
|
|
|
11/11
MIT Enterprise Forum of CT more
|
|
|
11/18
4:00 pm - 6:00 pm
CURE/Yale BioHaven Entrepreneurship Series: Helix
Therapeutics. Anlyan Center, Yale Medical School, New Haven. more
|
|
|
1/28
4:00 pm - 6:00 pm
CURE/Yale BioHaven Entrepreneurship Series: Advanced
Orthopedic Technologies/CardioPhotonics. Anlyan Center, Yale
Medical School, New Haven. more
|
|
|
February
CURE/Yale BioHaven Entrepreneurship Series: Arbor Fuel. Anlyan
Center, Yale Medical School, New Haven. more
|
|
|
|
2/10
MIT Enterprise Forum of CT more
|
|
|
|
3/10
MIT Enterprise Forum of CT more
|
|
|
3/11
4:00 pm - 6:00pm
CURE/Yale BioHaven
Entrepreneurship Series: Jonathan Rothberg. Anlyan Center,
Yale Medical School, New Haven. more
|
|
|
|
4/7
MIT Enterprise Forum of CT more
|
|
|
4/8
4:00 pm - 6:00 pm
CURE/Yale BioHaven
Entrepreneurship Series: Amarin Pharma Inc. Anlyan Center,
Yale Medical School, New Haven. more
|
|
|
|
5/5
MIT Enterprise Forum of CT more
|
|
|
5/12
4:00 pm - 6:00 pm
CURE/Yale BioHaven
Entrepreneurship Series: JS Genetics. Anlyan Center, Yale
Medical School, New Haven. more
|
|
|
5/26
4:00 pm - 6:00 pm
CURE/Yale BioHaven
Entrepreneurship Series: Kolltan Pharmaceuticals. Anlyan
Center, Yale Medical School, New Haven. more
|
|
|
|
|
To Increase
Tax Revenues, Grow the Tax Base
From the desk of Paul
Pescatello, President and CEO of CURE
 The
awarding of the Nobel prize last week to Yale's Thomas Steiz,
a co-founder of News Haven's Rib-X Pharmaceuticals,
underscores the important role that Connecticut bioscience
companies play in this all-important industry. But there is
still much work to be done to secure their place in the
state's economy. With that in mind, I thought it worthwhile to
republish an article by CURE Board member Harry Penner and
Christopher Levesque, CEO of CURE member company Affinimark
Technologies.
For the full story |
|
|
Connecticut
Biotech Founder Wins Nobel Prize
Thomas Steitz, M.D.,
Sterling professor of molecular biophysics and biochemistry
and professor of chemistry at Yale University, is one of three
winners of the 2009 Nobel Prize in Chemistry for his work
describing the structure and function of the ribosome, the
protein making factory key to the function of all life.
His close collaboration with
Yale faculty colleague Peter Moore and interactions with
William Jorgenson led to the establishment of a company, Rib-X
Pharmaceutical, Inc., which is using this knowledge of the
structures of the large ribosomal subunit and its antibiotic
complexes to create new classes of antibiotics.
For the full story
|
|
|
UConn: Drug
Price Regulation Can Hurt Investment
An article by faculty members of the UConn School of
Business suggests that any proposal for regulating the price
of drugs — even talk of a proposal — can have a negative
impact on the amount of money a company invests in
pharmaceutical research and development.
For the full story
|
|
|
Protein Sciences
Pursues Influenza Vaccines
Recent media interest in the swine flu (H1N1) has focused attention on
Protein Sciences Corporation.
Founded in 1983, Protein Sciences is a privately held vaccine company located in Meriden, CT. Its lead product candidates are vaccines to protect against seasonal and pandemic influenza.
For the full story |
Connecticut
Stem Cell Research Roundup
Connecticut
– the stem cell state
Beginning this issue, CURE News is pleased to report the
latest developments in stem cell research from around
Connecticut. This month: UConn Health
Center researchers in collaboration with scientists from
China have revealed the potential for human stem cells to
provide a vaccination against colon cancer.
For the full story |
CURE Member News Digest
 454
Life Sciences collaborates with SAIC-Frederick
Achillion completes Phase 1a
of ACH-1625 trial
Alexion drug granted orphan
status in Europe
Amarin extends bridge loan date
Applied Spine adds patients to
trial
Bayer HealthCare reports FDA
approval of Kogenate®
Boehringer Ingelheim concludes Phase 3
diabetes study
Bristol-Myers Squibb reports
ERBITUX® results
Connecticut Innovations invests in
Soft Tissue Regeneration
Danbury Hospital offers pediatric
pulmonology
GlaxoSmithKline gets Pandemrix™
authorization
HistoRx in partnership with Aperiop
Johnson
& Johnson collaborates with Crucell
MannKind presents
insulin data in Vienna
NanoViricides weighs
anti herpes application
Neurogen to be
acquired by Ligand
Pfizer oncology
unit starts Phase 3 trial
PhRMA
reports
record number of diabetes medicines
Protein Sciences proceeds
with swine flu vaccine
Rib-X
reports pact for gonorrhea treatment
Vascular
Insights reports varicose vein results
UConn team receives federal
funding for kidney modeling
Yale gets $36 million in
stimulus funds
For
the full story |
|
